- Home
- CRBP vs RCON Comparison
CRBP vs RCON Comparison
Compare CRBP & RCON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- RCON
- Stock Information
- Founded
- CRBP 2009
- RCON 2007
- Country
- CRBP United States
- RCON China
- Employees
- CRBP N/A
- RCON N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- RCON Oilfield Services/Equipment
- Sector
- CRBP Health Care
- RCON Energy
- Exchange
- CRBP Nasdaq
- RCON Nasdaq
- Market Cap
- CRBP 96.5M
- RCON 82.1M
- IPO Year
- CRBP N/A
- RCON 2009
- Fundamental
- Price
- CRBP $8.22
- RCON $2.55
- Analyst Decision
- CRBP Strong Buy
- RCON
- Analyst Count
- CRBP 10
- RCON 0
- Target Price
- CRBP $53.56
- RCON N/A
- AVG Volume (30 Days)
- CRBP 215.8K
- RCON 297.2K
- Earning Date
- CRBP 08-05-2025
- RCON 07-22-2025
- Dividend Yield
- CRBP N/A
- RCON N/A
- EPS Growth
- CRBP N/A
- RCON N/A
- EPS
- CRBP N/A
- RCON N/A
- Revenue
- CRBP N/A
- RCON $8,996,572.00
- Revenue This Year
- CRBP N/A
- RCON N/A
- Revenue Next Year
- CRBP $270.04
- RCON $12.17
- P/E Ratio
- CRBP N/A
- RCON N/A
- Revenue Growth
- CRBP N/A
- RCON N/A
- 52 Week Low
- CRBP $4.64
- RCON $1.39
- 52 Week High
- CRBP $61.90
- RCON $3.70
- Technical
- Relative Strength Index (RSI)
- CRBP 54.23
- RCON 58.62
- Support Level
- CRBP $7.26
- RCON $2.25
- Resistance Level
- CRBP $7.90
- RCON $2.61
- Average True Range (ATR)
- CRBP 0.53
- RCON 0.20
- MACD
- CRBP -0.01
- RCON -0.03
- Stochastic Oscillator
- CRBP 78.59
- RCON 76.36
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About RCON Recon Technology Ltd.
Recon Technology Ltd is an oilfield service company. The company is engaged in providing oilfield automation products, specialized equipment for oil and gas production and transportation, chemicals, and field services to petroleum companies mainly in the People's Republic of China (PRC). It has four reportable operating segments: Automation Product and Software, Equipment and Accessories, Platform outsourcing services, and Oilfield Environmental Protection. The majority of the firm's revenue comes from the Automation Product and Software segment which provides products and services like pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system among others.